Neurociencias
Departamento
Icahn School of Medicine at Mount Sinai
Nueva York, Estados UnidosPublicaciones en colaboración con investigadoras/es de Icahn School of Medicine at Mount Sinai (33)
2024
-
PsyCog: A computerised mini battery for assessing cognition in psychosis
Schizophrenia Research: Cognition, Vol. 37
2023
-
A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression
Journal of Clinical Investigation, Vol. 133, Núm. 22
-
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Movement Disorders, Vol. 38, Núm. 2, pp. 286-303
2022
-
Acidic nanoparticles protect against α-synuclein-induced neurodegeneration through the restoration of lysosomal function
Aging Cell, Vol. 21, Núm. 4
-
New insights into the genetic etiology of Alzheimer's disease and related dementias
Nature genetics, Vol. 54, Núm. 4, pp. 412-436
-
Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review
European Neuropsychopharmacology, Vol. 54, pp. 90-99
2021
-
Corrigendum to “Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action [European Neuropsychopharmacology (2020) 36, 121–136]” (European Neuropsychopharmacology (2020) 36 (121–136), (S0924977X20301802), (10.1016/j.euroneuro.2020.05.006))
European Neuropsychopharmacology
-
DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis – A narrative review from the ECNP bipolar disorders network
European Neuropsychopharmacology, Vol. 47, pp. 54-61
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques
Molecular Neurodegeneration, Vol. 16, Núm. 1
2020
-
Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers
Frontiers in Neuroscience, Vol. 14
-
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
The Lancet Neurology, Vol. 19, Núm. 1, pp. 71-80
-
Genealogy of the neurodegenerative diseases based on a meta-analysis of age-stratified incidence data
Scientific Reports, Vol. 10, Núm. 1
-
Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance
Movement Disorders, Vol. 35, Núm. 10, pp. 1755-1764
2019
-
Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls
Movement Disorders, Vol. 34, Núm. 9, pp. 1392-1398
-
Nanodelivery of therapeutic agents in Parkinson's disease
Progress in Brain Research (Elsevier B.V.), pp. 263-279
2017
-
Progressive changes in non-coding RNA profile in leucocytes with age
Aging, Vol. 9, Núm. 4, pp. 1202-1218
-
Whole-exome sequencing associates novel CSMD1 gene mutations with familial Parkinson disease
Neurology: Genetics, Vol. 3, Núm. 5
2016
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease
Movement Disorders, Vol. 31, Núm. 8, pp. 1192-1202